Psychedelic Alpha Bulletin 204: FDA keeps GH Research's 5-MeO-DMT on ice, new priority voucher pilot, PTSD treatment mentions, and fentanyl act halt

The Psychedelic Alpha Bulletin 204 compiles major US psychedelic drug and policy updates, anchored by FDA guidance affecting GH Research's 5-MeO-DMT development. The bulletin highlights how 5-MeO-DMT timelines remain constrained, alongside a Makary priority voucher pilot launch framed as a pathway to speed certain clinical and access processes. It also points to mentions of innovative PTSD treatment approaches and discusses how halting or changing the Fentanyl Act could streamline scheduling and regulatory timelines relevant to research and clinical programs.